↓ Skip to main content

Oncotarget

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

Overview of attention for article published in Oncotarget, February 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#11 of 14,317)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
50 Mendeley
Title
Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs
Published in
Oncotarget, February 2018
DOI 10.18632/oncotarget.24384
Pubmed ID
Authors

Derrick S. Haslem, Ingo Chakravarty, Gail Fulde, Heather Gilbert, Brian P. Tudor, Karen Lin, James M. Ford, Lincoln D. Nadauld

Abstract

The impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated. We report the overall survival and healthcare costs associated with precision oncology in these patients with advanced cancer. Building on a matched cohort study of 44 patients with metastatic cancer who received all of their care within a single institution, we evaluated the overall survival and healthcare costs for each patient. We analyzed the outcomes of 22 patients who received genomic testing and targeted therapy (precision oncology) between July 1, 2013 and January 31, 2015, and compared to 22 historically controlled patients (control) who received standard chemotherapy (N = 17) or best supportive care (N = 5). The median overall survival was 51.7 weeks for the targeted treatment group and 25.8 weeks for the control group (P = 0.008) when matching on age, gender, histological diagnosis and previous treatment lines. Average costs over the entire period were $2,720 per week for the targeted treatment group and $3,453 per week for the control group, (P = 0.036). A separate analysis of 1,814 patients with late-stage cancer diagnoses found that those who received a targeted cancer treatment (N = 93) had 6.9% lower costs in the last 3 months of life compared with those who did not. These findings suggest that precision oncology may improve overall survival for refractory cancer patients while lowering average per-week healthcare costs, resource utilization and end-of-life costs.

X Demographics

X Demographics

The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 50 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 20%
Other 6 12%
Student > Bachelor 6 12%
Student > Master 4 8%
Student > Ph. D. Student 3 6%
Other 5 10%
Unknown 16 32%
Readers by discipline Count As %
Medicine and Dentistry 11 22%
Biochemistry, Genetics and Molecular Biology 8 16%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Engineering 3 6%
Economics, Econometrics and Finance 2 4%
Other 7 14%
Unknown 16 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 475. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2022.
All research outputs
#56,531
of 25,411,814 outputs
Outputs from Oncotarget
#11
of 14,317 outputs
Outputs of similar age
#1,376
of 448,321 outputs
Outputs of similar age from Oncotarget
#1
of 441 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,317 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,321 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 441 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.